BOT 0.00% 38.0¢ botanix pharmaceuticals ltd

The credit raise was garbage, much the same as the DXB credit...

  1. 90 Posts.
    lightbulb Created with Sketch. 15
    The credit raise was garbage, much the same as the DXB credit raise. Same broker. All derisked and at a discount to boot. There will be some lovely Christmas cards this year.

    DXB was stuck at or about the CR price for a few months. It actually dipped slightly on a few days. The catalyst for the DXB SP rise was the licencing agreement for the ME. Up until than the stock was being traded in a tight range. The next rise will likely come from another licencing deal.

    BOT won't be licencing their product. So the catalyst for the SP will be revenue from the first month/quarter. Up until than, expect the bankers who were gifted a derisked asset at an 11% discount to trade the newly created 266 million shares in a similar range to that of DXB for the short term. Somewhere in the 0.30- 0.36 range would be my guess.

    All in my uneducated bitter opinion.
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.